Table 1 Baseline and clinical characteristics of 404 participants with prostate cancer from the PHS and HPFS
Characteristic | Non-lethal (n = 291) | Lethal (n = 113) |
|---|---|---|
Cohort, N (%) | ||
 PHS | 120 (41.2%) | 30 (26.5%) |
 HPFS | 171 (58.8%) | 83 (73.5%) |
Age at diagnosis, mean (SD) | 64.9 (6.2) | 67.5 (6.7) |
Clinical tumor stage, N (%)a | ||
 T1/T2 N0/Nx M0/Mx | 271 (94.1%) | 79 (72.5%) |
 T3 N0/Nx M0/Mx | 16 (5.6%) | 11 (10.1%) |
 T4/N1/M1 | 1 (0.3%) | 19 (17.4%) |
Gleason grade, N (%) | ||
 2–6 | 56 (19.2%) | 1 (0.9%) |
 3 + 4 | 126 (43.3%) | 13 (11.5%) |
 4 + 3 | 67 (23.0%) | 35 (31.0%) |
 8–10 | 42 (14.4%) | 64 (56.6%) |
PSA at diagnosis, ng/ml, N (%)b | Â | Â |
 0–3.9 | 29 (10.7%) | 4 (5.7%) |
 4–10 | 163 (60.1%) | 35 (50.0%) |
 10–19.9 | 54 (19.9%) | 15 (21.4%) |
 >20 | 25 (9.2%) | 16 (22.9%) |
Tissue from RP, N (%) | 283 (97.3%) | 86 (76.1%) |
BMI at diagnosis, mean (SD) | 25.1 (2.8) | 25.9 (3.3) |
BMI at baseline, mean (SD) | 24.6 (2.5) | 25.6 (3.2) |
Matched normal tissue available | 140 (48.1%) | 62 (54.9) |